Telix Pharmaceuticals Ltd (TLX) Stock
TLX has an Alpha Score of 65 out of 100 (moderate), computed on Nov 9, 2026 from 3 of 4 sub-scores. 1 of the hedge funds AlphaScala tracks reported TLX in 13F filings for the quarter ended Jun 30, 2026; the largest reported position is Marshall Wace's at $2.18M. Company insiders reported 1 open-market buy and 0 sales on SEC Form 4 in the 90 days to Nov 9, 2026. Its trailing P/E ratio is 2.9 (key statistics as of Apr 15, 2026).
What is TLX's Alpha Score?
How it works →Alpha Score of 65 reflects moderate overall profile with poor momentum, strong value, strong quality. Based on 3 of 4 signals – score is capped at 90 until remaining data ingests.
Computed from 3 of 4 sub-scores; a sub-score is left out when its inputs are missing, and the composite is capped accordingly.
Computed Nov 9, 2026
A rules-based research rating, not a recommendation to buy or sell.
Which hedge funds own TLX?
From 13F filings| Fund | Shares Held | Position Value | Change vs prior Q |
|---|---|---|---|
| Marshall Wace | 189K | $2.18M | NEW |
13F holdings as of Jun 30, 2026
Explore all tracked funds →Are Telix Pharmaceuticals Ltd insiders buying or selling?
SEC Form 4 filings| Date | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| Sep 7, 26 | Smith Darren Charlton | Group Chief Financial Officer | BUY | 2.1K | $20K |
SEC Form 4 filings as of Nov 9, 2026
See cluster-buy signals across all tickers →What are TLX's key statistics?
Key statistics as of Apr 15, 2026 · not updated for 209 days; newer filings may exist
TLX price chart
Powered by TradingViewWhat does Telix Pharmaceuticals Ltd do?
Telix Pharmaceuticals Ltd. is an innovative biotechnology company focused on the development of diagnostic and therapeutic products using molecularly-targeted radiation. The company's primary purpose is to enhance the accuracy of diagnostic imaging and provide targeted treatment options for cancer patients. Leveraging its expertise in radiopharmaceuticals, Telix Pharmaceuticals works extensively in areas such as oncology and theranostics, combining therapy with diagnostics to optimize patient treatment plans. Notably, its product pipeline addresses critical cancers, including prostate, kidney, and glioblastoma, reflecting the company's commitment to impacting major health challenges. Already playing a significant role in the burgeoning field of nuclear medicine, Telix Pharmaceuticals contributes to advancements in personalized medicine, aiming to improve clinical outcomes while minimizing side effects. As precision medicine continues to gain prominence in the healthcare market, Telix's innovations hold substantial potential for reshaping treatment paradigms and enhancing the efficacy of cancer care.